Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.
作者信息
Vo Phuong, Jaffe Elaine S, Cook Lisa, Ramos Catalina, Childs Richard
机构信息
Department of Internal Medicine, Newark Beth Israel Medical Center, Newark, NJ..
出版信息
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):e1-5. doi: 10.1016/j.clml.2013.05.006. Epub 2013 Aug 30.
Abstract
摘要
相似文献
1
Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.利妥昔单抗、硼替佐米、供体淋巴细胞和聚乙二醇化干扰素治疗异基因造血干细胞移植后第三次复发的套细胞淋巴瘤的持久缓解
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):e1-5. doi: 10.1016/j.clml.2013.05.006. Epub 2013 Aug 30.
2
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).未治疗的套细胞淋巴瘤采用 VcR-CVAD 联合维持利妥昔单抗的 2 期研究：东部肿瘤协作组研究（E1405）。
Blood. 2014 Mar 13;123(11):1665-73. doi: 10.1182/blood-2013-08-523845. Epub 2014 Jan 23.
3
Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.干细胞移植巩固治疗可提高任何诱导方案治疗后的套细胞淋巴瘤患者的生存率。
Exp Hematol. 2012 May;40(5):359-66. doi: 10.1016/j.exphem.2012.01.012. Epub 2012 Jan 21.
4
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.硼替佐米联合利妥昔单抗和地塞米松是复发和化疗耐药套细胞淋巴瘤患者的有效治疗方案。
Haematologica. 2011 Jul;96(7):1008-14. doi: 10.3324/haematol.2011.041392. Epub 2011 Apr 12.
5
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.硼替佐米-BEAM 联合自体造血干细胞移植治疗复发惰性非霍奇金淋巴瘤、转化型或套细胞淋巴瘤的 I/II 期研究。
Biol Blood Marrow Transplant. 2014 Apr;20(4):536-42. doi: 10.1016/j.bbmt.2014.01.004. Epub 2014 Jan 14.
6
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.利妥昔单抗和硼替佐米治疗复发或难治性套细胞和滤泡性淋巴瘤患者的 2 期临床试验。
Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14.
7
CCMCL1: a new model of aggressive mantle cell lymphoma.CCMCL1：侵袭性套细胞淋巴瘤的一种新模型。
Blood. 2015 Apr 23;125(17):2730-2. doi: 10.1182/blood-2015-01-622795.
8
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.苯达莫司汀、硼替佐米和利妥昔单抗联合治疗复发/难治性惰性和套细胞非霍奇金淋巴瘤患者。
Blood. 2011 Mar 10;117(10):2807-12. doi: 10.1182/blood-2010-11-314708. Epub 2011 Jan 14.
9
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.硼替佐米联合 CHOP-利妥昔单抗方案治疗初治弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤。
J Clin Oncol. 2011 Feb 20;29(6):690-7. doi: 10.1200/JCO.2010.31.1142. Epub 2010 Dec 28.
10
An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.自体或异基因干细胞移植的大剂量疗法在套细胞淋巴瘤中的作用的最新进展。
Curr Opin Oncol. 2004 Mar;16(2):106-13. doi: 10.1097/00001622-200403000-00004.
引用本文的文献
1
Role of allogeneic stem cell transplantation in mantle cell lymphoma.异基因干细胞移植在套细胞淋巴瘤中的作用。
Eur J Haematol. 2015 Apr;94(4):290-7. doi: 10.1111/ejh.12442. Epub 2014 Oct 18.
本文引用的文献
1
Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation.攻克套细胞淋巴瘤（MCL）：异基因干细胞移植的潜在益处。
Stem Cells Cloning. 2010 Jul 7;3:93-102. doi: 10.2147/sccaa.s7016.
2
Current and emerging new treatment strategies for mantle cell lymphoma.套细胞淋巴瘤的当前和新兴新治疗策略。
Leuk Lymphoma. 2013 May;54(5):912-21. doi: 10.3109/10428194.2012.726719. Epub 2013 Feb 19.
3
The evolving contribution of hematopoietic progenitor cells to lymphomagenesis.造血祖细胞在淋巴瘤发生中的不断贡献。
Blood. 2012 Sep 27;120(13):2553-61. doi: 10.1182/blood-2012-05-414995. Epub 2012 Aug 6.
4
New strategies in the treatment of mantle cell lymphoma.套细胞淋巴瘤治疗的新策略。
Clin Cancer Res. 2012 Jul 1;18(13):3499-508. doi: 10.1158/1078-0432.CCR-11-3152. Epub 2012 Jun 14.
5
Pharmacology and therapeutic potential of interferons.干扰素的药理学和治疗潜力。
Pharmacol Ther. 2012 Jul;135(1):44-53. doi: 10.1016/j.pharmthera.2012.03.006. Epub 2012 Mar 28.
6
Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.减低强度预处理异基因造血干细胞移植治疗复发/难治性套细胞淋巴瘤：多中心经验。
Ann Oncol. 2012 Oct;23(10):2695-2703. doi: 10.1093/annonc/mds054. Epub 2012 Mar 22.
7
Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.同种异体免疫疗法优化移植物抗肿瘤效应：概念与争议。
Hematology Am Soc Hematol Educ Program. 2011;2011:292-8. doi: 10.1182/asheducation-2011.1.292.
8
Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?异基因造血干细胞移植治疗套细胞淋巴瘤：我们现在在哪里，我们应该往哪里走？
Semin Hematol. 2011 Jul;48(3):227-39. doi: 10.1053/j.seminhematol.2011.03.009.
9
Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma.套细胞淋巴瘤自体干细胞移植后复发的模式和结果。
Cancer. 2011 May 1;117(9):1901-10. doi: 10.1002/cncr.25756. Epub 2010 Nov 29.
10
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.2008 年世界卫生组织淋巴造血组织肿瘤分类及以后：不断发展的概念和实际应用。
Blood. 2011 May 12;117(19):5019-32. doi: 10.1182/blood-2011-01-293050. Epub 2011 Feb 7.
Zotero 插件